Lynparza & Imfinzi combo reduced risk of disease progression or death by 37% vs. chemo and bevacizumab in patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations. Patients were treated with Imfinzi in combination with chemotherapy and bevacizumab followed by Imfinzi, Lynparza and